JP2016503397A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503397A5
JP2016503397A5 JP2015539720A JP2015539720A JP2016503397A5 JP 2016503397 A5 JP2016503397 A5 JP 2016503397A5 JP 2015539720 A JP2015539720 A JP 2015539720A JP 2015539720 A JP2015539720 A JP 2015539720A JP 2016503397 A5 JP2016503397 A5 JP 2016503397A5
Authority
JP
Japan
Prior art keywords
subject
agent
composition
heart failure
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015539720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503397A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066228 external-priority patent/WO2014066419A2/en
Publication of JP2016503397A publication Critical patent/JP2016503397A/ja
Publication of JP2016503397A5 publication Critical patent/JP2016503397A5/ja
Pending legal-status Critical Current

Links

JP2015539720A 2012-10-22 2013-10-22 心不全関連リスクおよびそれらと関連する因子を減少させる方法 Pending JP2016503397A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US61/716,867 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US61/822,752 2013-05-13
US201361839743P 2013-06-26 2013-06-26
US201361839750P 2013-06-26 2013-06-26
US61/839,743 2013-06-26
US61/839,750 2013-06-26
PCT/US2013/066228 WO2014066419A2 (en) 2012-10-22 2013-10-22 Methods for reducing risks associated with heart failure and factors associated therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018018942A Division JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Publications (2)

Publication Number Publication Date
JP2016503397A JP2016503397A (ja) 2016-02-04
JP2016503397A5 true JP2016503397A5 (enExample) 2016-12-08

Family

ID=50545459

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015539720A Pending JP2016503397A (ja) 2012-10-22 2013-10-22 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2018018942A Pending JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2019104270A Pending JP2019194193A (ja) 2012-10-22 2019-06-04 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018018942A Pending JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2019104270A Pending JP2019194193A (ja) 2012-10-22 2019-06-04 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Country Status (13)

Country Link
US (4) US20150246092A1 (enExample)
EP (5) EP4397314B1 (enExample)
JP (3) JP2016503397A (enExample)
KR (1) KR20160009008A (enExample)
CN (2) CN110193077A (enExample)
AU (2) AU2013334788A1 (enExample)
BR (1) BR112015009072A2 (enExample)
CA (1) CA2889155A1 (enExample)
ES (1) ES3058737T3 (enExample)
MX (1) MX2015005102A (enExample)
NI (1) NI201500057A (enExample)
PE (1) PE20151434A1 (enExample)
WO (1) WO2014066419A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
EP3474877A4 (en) * 2016-06-24 2019-11-27 University of Southern California MENTSH ANALOGUE AS THERAPEUTICS FOR DIABETES, ADIPOSITAS AND ASSOCIATED DISEASES AND COMPLICATIONS THEREOF
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
EP3603658B1 (en) * 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
EP2504032A4 (en) * 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
HK1215934A1 (zh) * 2012-12-06 2016-09-30 Stealth Peptides International, Inc. 肽治疗剂及其使用方法
CA2916497C (en) * 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Similar Documents

Publication Publication Date Title
Angeli et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
Selman et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches
Dagher et al. The hepatorenal syndrome
Sezai et al. Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study
Browne et al. Pathophysiology of pulmonary complications of acute pancreatitis
Ahmadi et al. Thyroid gland dysfunction and its effect on the cardiovascular system: a comprehensive review of the literature
TWI505827B (zh) 治療高尿酸血症及與高尿酸血症有關之新陳代謝疾病之方法及組合物
Ergul Endothelin‐1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents
JP2016522196A5 (enExample)
JP2022137224A (ja) 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ
JP2016511259A5 (enExample)
Kitakaze et al. levation of Plasma Adenosine Levels May Attenuate the Severity of Chronic Heart Failure
JP2006502152A (ja) 線維性疾患治療用の併用療法
Shibahara et al. Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD
Møller et al. Pathogenesis and pathophysiology of hepatorenal syndrome–is there scope for prevention?
Medarov et al. Clinical aspects of portopulmonary hypertension
Xu et al. Protective role of AT2 and B1 receptors in kinin B2-receptor-knockout mice with myocardial infarction
van der Jagt et al. Beta-blockers in intensive care medicine: potential benefit in acute brain injury and acute respiratory distress syndrome
Ye et al. Inhibition of the P2X7 receptor prevents atrial proarrhythmic remodeling in experimental post-operative atrial fibrillation
McBride et al. Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management
Rosseel et al. Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
WO2023183339A1 (en) Selective vasopressin receptor agonist for end-stage liver disease
JP2021530517A5 (enExample)
Kupferschmid et al. Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy